Recursion

AI-first drug design built on AlphaFold for pharma R&D.

Isomorphic Labs is an AI-first drug discovery company spun out of Google DeepMind, building generative and predictive ML models for molecular design and drug-performance prediction. Its Drug Design Engine builds on AlphaFold to advance internal and partnered pipelines with Eli Lilly, Novartis, and J&J. It is a drug-discovery company that works through pharma R&D partnerships rather than a self-serve product.

Generative AI drug discovery — the end-to-end Pharma.ai suite.

Insilico Medicine is a clinical-stage drug discovery company whose Pharma.ai suite applies generative AI across the pipeline: PandaOmics for target identification, Chemistry42 for de novo molecule design, and inClinico for clinical-trial outcome prediction. The cloud software is licensed to pharma, and the company says it serves 13 of the top 20 global drugmakers. It also runs its own internal pipeline of AI-discovered drug candidates.

Foundation models for molecular structure and antibody design.

Chai Discovery builds foundation models for drug discovery — Chai-1 for biomolecular structure prediction across proteins, ligands, DNA/RNA, and glycans, and Chai-2 for de novo antibody design. Chai-1 weights and inference code are released for non-commercial use, and a free web server runs the model in-browser. It is both a model provider and a usable platform.

Generative protein language models that design novel proteins.

Profluent uses generative AI — its ProGen-lineage protein language models — to author novel proteins from scratch or from natural scaffolds, for medicine and agriculture. It released OpenCRISPR-1, described as the first AI-designed gene editor (open-licensed and published in Nature), and is expanding into antibodies and enzymes. It operates as an AI protein-design company working through partnerships with open-sequence releases, not a self-serve consumer platform.